REVIVE THERAPEUTICS LTD (RVVTF)
RVVTF moved a median of +1.42% 30 minutes after news, and +1.82% by the close. How RVVTF actually reacts to news — the realized, point-in-time move the market made, measured across 51 labeled events over the last three years with zero look-ahead.
RVVTF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 46 |
| 30-min | +1.42% | 58% | 48 |
| 60-min | +1.73% | 62% | 50 |
| to close | +1.82% | 57% | 49 |
| Middle 50% of RVVTF reactions | -0.33% to +10.04% |
|---|---|
| Median reaction (30-min) | +1.42% |
| Measured reactions | 51 |
Half of all REVIVE THERAPEUTICS LTD news events land between -0.33% and +10.04% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when RVVTF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RVVTF's baseline. Nothing else.
Recent RVVTF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases | Press release | ACCESS Newswire | — | +14.93% | |
| Revive Therapeutics Announces Proposed Shares for Debt Settlement | Press release | ACCESS Newswire | — | -0.48% | |
| Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | Press release | ACCESS Newswire | +0.00% | +6.67% | |
| Revive Therapeutics Reports Grant of Options | Press release | ACCESS Newswire | +50.00% | +17.20% | |
| Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study | Press release | ACCESS Newswire | +0.50% | +11.31% | |
| Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement | Press release | ACCESS Newswire | +0.00% | — | |
| Revive Therapeutics Announces Proposed Private Placement | Press release | ACCESS Newswire | +0.00% | -4.33% | |
| Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures | Press release | ACCESS Newswire | +15.50% | +37.50% | |
| Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases | Press release | ACCESS Newswire | +4.61% | +85.53% | |
| Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | Press release | GlobeNewswire | +33.08% | -2.60% | |
| Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study | Press release | GlobeNewswire | — | -2.90% | |
| Revive Therapeutics Announces Closing of Second Tranche of Private Placement | Press release | GlobeNewswire | +0.00% | -5.46% | |
| Revive Therapeutics Announces Extension of Proposed Private Placement | Press release | GlobeNewswire | +22.03% | +22.03% | |
| Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement | Press release | GlobeNewswire | +20.80% | — | |
| Revive Therapeutics Announces Proposed Private Placement and Debt Settlement | Press release | GlobeNewswire | +0.00% | -2.56% | |
| Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study | Press release | GlobeNewswire | +21.62% | +1.35% | |
| Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity | Press release | GlobeNewswire | -0.67% | +0.00% | |
| Revive Therapeutics Advances with Next-Generation Bucillamine Development | Press release | GlobeNewswire | +0.00% | -4.05% | |
| Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Press release | GlobeNewswire | — | +0.00% | |
| Revive Therapeutics Announces Proposed Shares for Debt Transaction | Press release | GlobeNewswire | -0.47% | -9.72% | |
| Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment | Press release | GlobeNewswire | -2.90% | -2.90% | |
| Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program | Press release | GlobeNewswire | +0.00% | +140.38% | |
| Revive Therapeutics Announces Results of Annual Shareholder Meeting | Press release | GlobeNewswire | +1.61% | +15.48% | |
| Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program | Press release | GlobeNewswire | +37.65% | +17.65% | |
| Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures | Press release | GlobeNewswire | +0.00% | +9.09% | |
| Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Press release | GlobeNewswire | +27.45% | +14.71% | |
| Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke | Press release | GlobeNewswire | +0.74% | +0.00% | |
| Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Press release | GlobeNewswire | +0.00% | -3.13% | |
| Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures | Press release | GlobeNewswire | -6.67% | +20.00% | |
| Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections | Press release | GlobeNewswire | -21.16% | -14.73% | |
| Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure | Press release | GlobeNewswire | — | +1.00% | |
| Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID | Press release | GlobeNewswire | +10.79% | +11.51% | |
| Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product | Press release | GlobeNewswire | +0.25% | -8.72% | |
| Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID | Press release | GlobeNewswire | +28.00% | +14.86% | |
| Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product | Press release | GlobeNewswire | +0.00% | -2.91% | |
| Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder | Press release | GlobeNewswire | +10.00% | +15.00% | |
| Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID | Press release | GlobeNewswire | +11.11% | +25.00% | |
| Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID | Press release | GlobeNewswire | +16.82% | +1.82% | |
| Revive Therapeutics Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +20.83% | |
| Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110 | Press release | GlobeNewswire | +0.00% | +13.99% | |
| Revive Therapeutics Explores the Use of Bucillamine for Long COVID | Press release | GlobeNewswire | +1.54% | -5.96% | |
| Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500 | Press release | GlobeNewswire | +1.54% | -5.96% | |
| Revive Therapeutics Ltd. Announces Offering of Up to $3 Million | Press release | GlobeNewswire | -22.49% | -16.72% | |
| Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada | Press release | GlobeNewswire | +9.54% | +1.66% | |
| Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine | Press release | GlobeNewswire | +10.96% | +10.96% | |
| Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders | Press release | GlobeNewswire | +0.00% | +2.08% | |
| Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine | Press release | GlobeNewswire | +0.00% | -3.00% | |
| Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development | Press release | GlobeNewswire | +0.00% | +4.26% | |
| Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test | Press release | GlobeNewswire | -13.24% | -4.11% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RVVTF section they belong to.
Where else RVVTF is measured.
RVVTF earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LIMITLESS VENTURE GRP INC (LVGI) | 51 | 0.00% | 33% |
| Invitae Corporation (NVTA) | 51 | +0.86% | 58% |
| Ventripoint Diagnostics Ltd (VPT_CDNX) | 51 | -1.92% | 39% |
| Onconova Therapeutics, Inc. (ONTX) | 50 | +0.88% | 65% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is REVIVE THERAPEUTICS LTD's median reaction calculated?
Every labeled RVVTF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 51 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of RVVTF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RVVTF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.